Clinical Trials · NCT05159752
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Clinuvel Europe Limited
- Enrollment
- 6
- Start date
- Oct 2021
- Locations
- 1 site, Germany
- Primary endpoint
- Change in minimal erythema dose (MED).